Novo Nordisk UK has announced that Ozempic (semaglutide), a new once-weekly GLP-1 analogue injection for the treatment of Type 2 diabetes is now available in the UK. Ozempic works by mimicking the function of the GLP-1 (human glucagon-like peptide-1) hormone produced in the read more »